AbbVie and J&J look to broaden Imbruvica's use; Theravance and Mylan kick off COPD Phase III;

@FierceBiotech: ICYMI: FierceBiotech Radio on GSK's latest setback, Kyle Bass' 'truthful irrelevancy,' and Horizon's web presence. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: UPDATED: Melinta's CEO steps down amid a big Phase III push. Article | Follow @JohnCFierce

> Shire ($SHPG) is reportedly considering sweetening its offer for Baxalta ($BXLT) after a $30 billion, all-stock proposal received a lukewarm reception from shareholders. More

> Partners Theravance ($TBPH) and Mylan ($MYL) started Phase III development of revefenacin, a new COPD treatment. News

> AbbVie ($ABBV) and Johnson & Johnson ($JNJ) are working to expand the label for their cancer drug Imbruvica, filing for FDA approval in treatment-naive chronic lymphocytic leukemia. Item

Medical Device News

@FierceMedDev: ICYMI Friday: Startup Velico nabs another $15.5M from BARDA for dried plasma tech. Story | Follow @FierceMedDev

@EmilyWFierce: A little background on the FDA's regulation of drug marketing. More from The Atlantic | Follow @EmilyWFierce

> Qualcomm buys medical device connectivity player Capsule Tech. More

> Cantel to buy endoscope cleanliness startup for $80M. Article

Pharma News

@FiercePharma: ICYMI: Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. Story | Follow @CarlyHFierce

> Shire casts about for creative ways to woo Baxalta shareholders. Story

> Advera Health Analytics: Merck statins linked to more muscle side effects than rest of class. Article

Animal Health News

> Phibro doubles earnings as demand for specialty animal products skyrockets. More

> Regulatory challenges top of mind at inaugural ACI animal health forum. Report

> FDA issues groundbreaking rules for manufacturing safe pet foods. Story

> McDonald's commits to cage-free eggs. Item

> USDA, poultry producers warn MN officials to expect bird flu resurgence. Article

Biotech IT News

> IBM inks deals to give Watson a role in R&D at Icon and Teva. News

> GSK picks Siemens as preferred supplier of automation tech. Report

> HudsonAlpha pairs HiSeq X Ten with Dragen processor to boost throughput. More

> Adaptimmune poaches GSK vet to lead biometrics team. Story

> AstraZeneca commits $18M to clinical trial bioinformatics collaboration. Article

Pharma Marketing News

> Surprise: J&J moves $1B U.S. media buying account back to Interpublic. Article

> Sanofi's combo med LixiLan ready to go to FDA in ongoing scramble for diabetes dominance. Report

> Diabetes rivalries get more complicated with new FDA warning on J&J's Invokana. Story

> AstraZeneca's lauded 'Take it From a Fish' campaign scores again at Clio Healthcare awards. More

> AZ's high-powered Crestor could gain from payer limits on PCSK9 meds. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.